Table Graph
   

Non replicating viral vector - versus control - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.19 [0.06, 0.64]< 10%2 studies (2/-)99.6 %some concernnot evaluable moderatecrucial-
hospitalization 0.18 [0.03, 1.17]< 10%1 study (1/-)96.3 %NAnot evaluable important-
symptomatic Covid-19 0.33 [0.28, 0.39]< 10%2 studies (2/-)100.0 %some concernnot evaluable moderateimportant-
asymptomatic COVID case 0.33 [0.23, 0.48]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
infection (PCR positive symptomatic or not) 0.44 [0.33, 0.59]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
severe COVID-19 occurrence 0.24 [0.12, 0.48]< 10%2 studies (2/-)100.0 %some concernnot evaluable moderatenon important-
vaccine efficacy after dose 1 (and before dose 2) 0.24 [0.14, 0.41]< 10%1 study (1/-)100.0 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.86 [0.64, 1.17]< 10%1 study (1/-)82.5 %NAnot evaluable important-
ATE (Myocardial infarction or ischemic stroke) 0.50 [0.12, 2.00]< 10%1 study (1/-)83.6 %NAnot evaluable non important-
deep vein thrombosis 3.00 [0.61, 14.86]< 10%1 study (1/-)9.0 %NAnot evaluable non important-
Guillain-Barré syndrome 1.00 [0.06, 15.98]< 10%1 study (1/-)50.0 %NAnot evaluable non important-
ischemic stroke 0.67 [0.11, 3.99]< 10%1 study (1/-)67.1 %NAnot evaluable non important-
Myocardial infarction 1.00 [0.02, 50.39]< 10%1 study (1/-)50.0 %NAnot evaluable non important-
pericarditis 2.00 [0.07, 59.60]< 10%1 study (1/-)34.7 %NAnot evaluable non important-
pulmonary embolism 4.00 [0.45, 35.79]< 10%1 study (1/-)10.9 %NAnot evaluable non important-
venous thromboembolism 2.75 [0.88, 8.64]< 10%1 study (1/-)4.2 %NAnot evaluable non important-

AE of interest endpoints 00

cerebral venous sinus thrombosis (CVST) 2.00 [0.07, 59.60]< 10%1 study (1/-)34.7 %NAnot evaluable important-
appendicitis 1.20 [0.37, 3.93]< 10%1 study (1/-)38.2 %NAnot evaluable non important-
Bell's palsy 1.18 [0.36, 3.89]< 10%2 studies (2/-)39.3 %some concernnot evaluable moderatenon important-
immediate allergic reaction 1.95 [0.07, 58.15]< 10%1 study (1/-)35.2 %NAnot evaluable non important-
multiple sclerosis 1.95 [0.07, 58.15]< 10%1 study (1/-)35.2 %NAnot evaluable non important-
myelitis 1.95 [0.18, 21.52]< 10%1 study (1/-)29.4 %NAnot evaluable non important-
Potential Immune Gastrointestinal disorders 0.33 [0.03, 3.13]< 10%1 study (1/-)83.3 %NAnot evaluable non important-
Potential Immune Musculoskeletal disorders 0.98 [0.06, 15.60]< 10%1 study (1/-)50.7 %NAnot evaluable non important-
Potential Immune Neuroinflammatory disorders 1.22 [0.33, 4.54]< 10%1 study (1/-)38.4 %NAnot evaluable non important-
Potential Immune Skin disorders 0.73 [0.16, 3.27]< 10%1 study (1/-)65.8 %NAnot evaluable non important-
Potential Immune Vasculitides 0.49 [0.02, 14.54]< 10%1 study (1/-)65.9 %NAnot evaluable non important-
Thromboembolic events 0.49 [0.15, 1.62]< 10%1 study (1/-)87.9 %NAnot evaluable non important-

reactogenicity (vaccines) endpoints 00

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons